Marcel Smid

List of Publications by Citations

Source: https://exaly.com/author-pdf/7470639/marcel-smid-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

80
papers

4,790
citations

h-index

88
6,002
ext. papers

8.6
avg, IF

L-index

#	Paper	IF	Citations
80	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. <i>Nature</i> , 2016 , 534, 47-	5 9 0.4	1193
79	Subtypes of breast cancer show preferential site of relapse. Cancer Research, 2008, 68, 3108-14	10.1	563
78	Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 13021-6	11.5	334
77	Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. <i>Cell</i> , 2013 , 154, 1060-1073	56.2	296
76	Genes associated with breast cancer metastatic to bone. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2261-7	2.2	253
75	Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. <i>PLoS ONE</i> , 2014 , 9, e103988	3.7	228
74	mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. <i>Clinical Cancer Research</i> , 2011 , 17, 3600-18	12.9	192
73	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). <i>Modern Pathology</i> , 2015 , 28, 807-21	9.8	142
72	miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. <i>Breast Cancer Research</i> , 2013 , 15, R33	8.3	140
71	The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. <i>Nature Genetics</i> , 2019 , 51, 1450-1458	36.3	121
70	Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. <i>Nature Communications</i> , 2016 , 7, 12910	17.4	74
69	Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes. <i>Breast Cancer Research and Treatment</i> , 2011 , 128, 23-30	4.4	67
68	A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer. <i>Cancer Research</i> , 2017 , 77, 3814-3822	10.1	56
67	The circular RNome of primary breast cancer. <i>Genome Research</i> , 2019 , 29, 356-366	9.7	55
66	A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers. <i>Nature Genetics</i> , 2017 , 49, 341-348	36.3	54
65	Selection of personalized patient therapy through the use of knowledge-based computational models that identify tumor-driving signal transduction pathways. <i>Cancer Research</i> , 2014 , 74, 2936-45	10.1	51
64	Cancer-associated fibroblast-derived Gremlin 1 promotes breast cancer progression. <i>Breast Cancer Research</i> , 2019 , 21, 109	8.3	42

(2018-2018)

63	Interferon-Stimulated Genes Are Involved in Cross-resistance to Radiotherapy in Tamoxifen-Resistant Breast Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 3397-3408	12.9	41
62	T lymphocytes facilitate brain metastasis of breast cancer by inducing Guanylate-Binding Protein 1 expression. <i>Acta Neuropathologica</i> , 2018 , 135, 581-599	14.3	38
61	DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity. <i>Molecular Oncology</i> , 2014 , 8, 458-68	7.9	37
60	mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients. <i>Molecular Oncology</i> , 2015 , 9, 920-32	7.9	34
59	MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. <i>PLoS ONE</i> , 2019 , 14, e027	164,00	33
58	Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 439-48	4.4	33
57	Gene length corrected trimmed mean of M-values (GeTMM) processing of RNA-seq data performs similarly in intersample analyses while improving intrasample comparisons. <i>BMC Bioinformatics</i> , 2018 , 19, 236	3.6	32
56	A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy. <i>Breast Cancer Research</i> , 2019 , 21, 77	8.3	32
55	Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer. <i>Cancer Letters</i> , 2015 , 362, 36-44	9.9	31
54	Functional Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects. <i>Clinical Cancer Research</i> , 2018 , 24, 6277-6287	12.9	31
53	Molecular characteristics of circulating tumor cells resemble the liver metastasis more closely than the primary tumor in metastatic colorectal cancer. <i>Oncotarget</i> , 2016 , 7, 59058-59069	3.3	31
52	Uncovering the signaling landscape controlling breast cancer cell migration identifies novel metastasis driver genes. <i>Nature Communications</i> , 2019 , 10, 2983	17.4	29
51	Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines. <i>BMC Cancer</i> , 2016 , 16, 34	4.8	28
50	4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer. <i>Molecular Oncology</i> , 2016 , 10, 24-39	7.9	27
49	PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. <i>Acta Neuropathologica Communications</i> , 2015 , 3, 88	7.3	27
48	Mitochondrial DNA content in breast cancer: Impact on in vitro and in vivo phenotype and patient prognosis. <i>Oncotarget</i> , 2016 , 7, 29166-76	3.3	27
47	The advantage of laser-capture microdissection over whole tissue analysis in proteomic profiling studies. <i>Proteomics</i> , 2016 , 16, 1474-85	4.8	26
46	Epithelial-Mesenchymal Transition in Human Prostate Cancer Demonstrates Enhanced Immune Evasion Marked by IDO1 Expression. <i>Cancer Research</i> , 2018 , 78, 4671-4679	10.1	25

45	Confirmation of a metastasis-specific microRNA signature in primary colon cancer. <i>Scientific Reports</i> , 2018 , 8, 5242	4.9	24
44	An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients. <i>BMC Cancer</i> , 2016 , 16, 123	4.8	20
43	Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer. <i>Scientific Reports</i> , 2017 , 7, 2099	4.9	19
42	Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation. <i>Nature Communications</i> , 2019 , 10, 1749	17.4	19
41	Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial. <i>European Journal of Cancer</i> , 2017 , 75, 33-40	7.5	18
40	GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease. <i>Cancer Letters</i> , 2016 , 376, 104-9	9.9	18
39	Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer. <i>Oncotarget</i> , 2016 , 7, 3098-110	3.3	16
38	Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer. <i>International Journal of Cancer</i> , 2019 , 145, 1083-1089	7.5	15
37	Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes. <i>Molecular Oncology</i> , 2015 , 9, 877-88	7.9	14
36	Predicting paclitaxel-induced neutropenia using the DMET platform. <i>Pharmacogenomics</i> , 2015 , 16, 123	1- <u>4</u> .6	14
36 35	Predicting paclitaxel-induced neutropenia using the DMET platform. <i>Pharmacogenomics</i> , 2015 , 16, 123 Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer. <i>Breast Cancer Research</i> , 2019 , 21, 151	1 -4. 6	14
	Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in	8.3	
35	Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer. <i>Breast Cancer Research</i> , 2019 , 21, 151 Clonality, Antigen Recognition, and Suppression of CD8 T Cells Differentially Affect Prognosis of	8.3	14
35	Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer. <i>Breast Cancer Research</i> , 2019 , 21, 151 Clonality, Antigen Recognition, and Suppression of CD8 T Cells Differentially Affect Prognosis of Breast Cancer Subtypes. <i>Clinical Cancer Research</i> , 2020 , 26, 505-517 Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant	8.3	14
35 34 33	Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer. <i>Breast Cancer Research</i> , 2019 , 21, 151 Clonality, Antigen Recognition, and Suppression of CD8 T Cells Differentially Affect Prognosis of Breast Cancer Subtypes. <i>Clinical Cancer Research</i> , 2020 , 26, 505-517 Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel. <i>Cancers</i> , 2019 , 11, Co-regulated gene expression of splicing factors as drivers of cancer progression. <i>Scientific Reports</i> ,	8.3 12.9 6.6	14 13 10
35 34 33 32	Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer. <i>Breast Cancer Research</i> , 2019 , 21, 151 Clonality, Antigen Recognition, and Suppression of CD8 T Cells Differentially Affect Prognosis of Breast Cancer Subtypes. <i>Clinical Cancer Research</i> , 2020 , 26, 505-517 Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel. <i>Cancers</i> , 2019 , 11, Co-regulated gene expression of splicing factors as drivers of cancer progression. <i>Scientific Reports</i> , 2019 , 9, 5484 ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with	8.3 12.9 6.6	14 13 10
35 34 33 32 31	Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer. <i>Breast Cancer Research</i> , 2019 , 21, 151 Clonality, Antigen Recognition, and Suppression of CD8 T Cells Differentially Affect Prognosis of Breast Cancer Subtypes. <i>Clinical Cancer Research</i> , 2020 , 26, 505-517 Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel. <i>Cancers</i> , 2019 , 11, Co-regulated gene expression of splicing factors as drivers of cancer progression. <i>Scientific Reports</i> , 2019 , 9, 5484 ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen. <i>Cancers</i> , 2020 , 12, Vascular pattern analysis for the prediction of clinical behaviour in pheochromocytomas and	8.3 12.9 6.6 4.9	14 13 10 10

(2015-2020)

27	Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes 2020 , 8,		9
26	Prognostic significance of nuclear expression of UMP-CMP kinase in triple negative breast cancer patients. <i>Scientific Reports</i> , 2016 , 6, 32027	4.9	8
25	The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome. <i>Cancers</i> , 2018 , 10,	6.6	8
24	MicroRNA expression in pre-treatment plasma of patients with benign breast diseases and breast cancer. <i>Oncotarget</i> , 2018 , 9, 24335-24346	3.3	8
23	Integrative analysis of genomic amplification-dependent expression and loss-of-function screen identifies ASAP1 as a driver gene in triple-negative breast cancer progression. <i>Oncogene</i> , 2020 , 39, 4118	3-24731	7
22	Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. <i>Nature Communications</i> , 2021 , 12, 5668	17.4	7
21	Proteomic characterization of microdissected breast tissue environment provides a protein-level overview of malignant transformation. <i>Proteomics</i> , 2017 , 17, 1600213	4.8	6
20	High mRNA expression of splice variant SYK short correlates with hepatic disease progression in chemonaive lymph node negative colon cancer patients. <i>PLoS ONE</i> , 2017 , 12, e0185607	3.7	6
19	A Method to Correlate mRNA Expression Datasets Obtained from Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Tissue Samples: A Matter of Thresholds. <i>PLoS ONE</i> , 2015 , 10, e0144097	3.7	6
18	Molecular Comparison of Imatinib-NaWe and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs. <i>Cancers</i> , 2019 , 11,	6.6	5
17	Differential reprogramming of breast cancer subtypes in 3D cultures and implications for sensitivity to targeted therapy. <i>Scientific Reports</i> , 2021 , 11, 7259	4.9	5
16	Mitochondrial RNA Expression and Single Nucleotide Variants in Association with Clinical Parameters in Primary Breast Cancers. <i>Cancers</i> , 2018 , 10,	6.6	5
15	Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features. <i>Nature Communications</i> , 2021 , 12, 574	17.4	5
14	Intratumoral heterogeneity of second-harmonic generation scattering from tumor collagen and its effects on metastatic risk prediction. <i>BMC Cancer</i> , 2020 , 20, 1217	4.8	4
13	Apolipoprotein B mRNA-Editing Catalytic Polypeptide-Like-Induced Protein Changes in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Throughout Disease Progression <i>JCO Precision Oncology</i> , 2022 , 6, e2100190	3.6	2
12	Fusion transcripts and their genomic breakpoints in polyadenylated and ribosomal RNA-minus RNA sequencing data. <i>GigaScience</i> , 2021 , 10,	7.6	2
11	Downregulation of matrix Gla protein is a biomarker for tamoxifen-resistant and radioresistant breast cancer. <i>Biomarkers in Medicine</i> , 2019 , 13, 841-850	2.3	1
10	Global proteomic characterization of microdissected estrogen receptor positive breast tumors. <i>Data in Brief</i> , 2015 , 5, 399-402	1.2	1

9	Identification of potential molecular biomarkers for response of soft tissue sarcoma to eribulin: Translational results of EORTC trial 62052 <i>Journal of Clinical Oncology</i> , 2013 , 31, 10573-10573	2.2	1	
8	Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer. <i>Scientific Reports</i> , 2020 , 10, 22292	4.9	1	
7	Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating Etatenin mutations. <i>European Journal of Surgical Oncology</i> , 2019 , 45, 691-698	3.6	1	
6	A panel of DNA methylation markers for the classification of consensus molecular subtypes 2 and 3 in patients with colorectal cancer. <i>Molecular Oncology</i> , 2021 , 15, 3348-3362	7.9	O	
5	Response. Journal of the National Cancer Institute, 2014 , 106,	9.7		
4	Gene expression profiles of primary tumors versus circulating tumor cells in metastatic breast cancer <i>Journal of Clinical Oncology</i> , 2014 , 32, 11017-11017	2.2		
3	A pharmacogenetic model predicting low paclitaxel clearance based on the DMET platform Journal of Clinical Oncology, 2013 , 31, 2597-2597	2.2		
2	A panel of DNA methylation markers for the classification of consensus molecular subtypes 2 and 3 in patients with colorectal cancer <i>Journal of Clinical Oncology</i> , 2021 , 39, 3545-3545	2.2		
1	A tale on rabbit ears and pan-handles, the rings that rule all. <i>EBioMedicine</i> , 2019 , 49, 17-18	8.8		